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Abstract
The present study is focused on the development of doxycycline loaded calcium–deficient hydroxyapatite 
(CDHA) microspheres for the treatment of periodontitis. The CDHA microspheres were formed by liquid 
immiscibility effect using gelatin and paraffin oil with varying Ca/P ratios using calcium hydroxide and 
diammonium hydrogen orthophosphate as precursors. The morphology of the microspheres as characterized 
by SEM was optimized by varying the gelatin content. The doxycycline incorporation and its release profiles 
were studied by UV-Visible spectroscopy in phosphate buffer at physiological conditions. The pH of the buffer 
solution was initially optimized to have maximum amount of drug loading. Doxycycline loading around the 
physiological pH of 7 has the highest amount of drug incorporation. All the microspheres exhibit similar 
release profiles with an initial gradual increase reaching a maximum value and then nearly constant release. 
The microspheres formed using 6% gelatin shows maximum amount of drug release of 80%.
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Introduction
The poor blood circulation in osseous tissue is the 
main cause of the reduced therapeutic effects of 
administered drugs at the site of bone infections and 
necessitates the supply of large doses of antibiotics 
systematically to achieve clinically favorable 
results1. Ceramic particulate delivery systems with 
incorporated drugs are evaluated as an alternative for 
effective treatment of bone diseases2. Recently novel 
strontium substituted calcium phosphate cement 
loaded with doxycycline hyclate has also been used 
to elucidate the effect of strontium substitution 
on antibiotic delivery3. Delivery of active agents by 
resorbable bioceramics such as tricalcium phosphate 
(TCP), calcium–deficient hydroxyapatite (CDHA) 
and biphasic calcium phosphate (BCP) ceramics 
(consisting of hydroxyapatite (HA) and TCP phases) 
have been frequently reported for orthopedic uses4,5. 
The mineral component of bone is essentially CDHA 
which is structurally similar to stoichiometric HA 
(Ca/P = 1.67) but compositionally has a Ca/P ratio of 
about 1.5 which is similar to TCP.  The CDHAs with 
Ca/P ratios ranging from 1.67 to 1.33 originate from 
the loss of Ca 2+ ions from the unit cell and hence 
the name calcium deficient hydroxyapatite with the 
formula Ca 
10-x 
(HPO4) x (PO4) 6-x (OH) 2-x 
6.
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Doxycyclin is a broad-spectrum antibiotic 
extensively used for lyme disease, brucellosis, and 
several rickettsial infections. It is the drug of choice in 
the treatment of periodontitis which is one of the main 
causes of tooth loss. The formation of periodontal 
pockets between the teeth and gums promotes the 
growth of aggressive forms of bacteria7. However, 
the periodontal pockets are easily accessible from 
the oral cavity and so provide a convenient site 
for local treatment by drug delivery systems. In an 
earlier study we have shown the controlled release 
of doxycycline by BCP ceramics8which is a two 
phase system.  The present study is focused on the 
preparation of single phase CDHA microspheres; its 
cha racterization and doxycycline release profiles for 
the treatment of periodontal diseases.
Materials and Methods
High purity calcium hydroxide [Ca(OH)
2
] and 
diammonium hydrogen orthophosphate (DAP, 
(NH4)
2
HPO4) were used for the preparation of 
CDHA powder (Sigma Aldrich Chemicals, USA). 
Pharmaceutical grade low viscosity paraffin oil, 
gelatin (bovine source, SD fine chemicals, India), and 
the antibacterial drug doxycyclin hyclate (Periostat, 
Ranbaxy Pharmaceuticals, India) were procured 
locally. The CDHA powder was synthesized by the 
microwave method. Weighed amounts of the starting 
granules were dissolved in water and the DAP solution 
was added to the calcium hydroxide solution under 
stirr ing conditions. The solution was then exposed 
to microwave irradiation in a microwave oven (BPL, 
India). The product was then filtered and dried in 
an oven at 1000C.  Three different CDHA systems 
were prepared by varying the Ca/P molar ratio to 
1.56, 1.61, 1.64 and the samples have been coded 
as CD156, CD161, and CD164 respectively.
An appropriate aqueous solution of gelatin 
content was prepared at 30oC. Fine CD161 powder 
were added to the above solution and the gelatin 
slurry with CDHA powder was dispersed in light pa-
raffin oil in an analytical flask by stirring with a glass 
paddle stirrer. The rpm of the stirrer and the time 
of stirring were optimized to form microspheres. 
The precipitated microspheres were washed in 
acetone followed by ethanol and dried in air. The 
gelatin bound beads were heated for an hour at 
550оC to burn off the gelatin and the microspheres 
were then thoroughly washed in distilled water to 
remove any unburned gelatin and dried in an oven. 
The microspheres formed with 4% (4g in 100 ml), 
6% (6g in 100 ml), and 8% (8g in 100 ml) gelatin 
have been coded as 4CD161MS, 6CD161MS, and 
8CD161MS respectively in the text.  The same 
process was repeated for other CDHA powder and 
the microspheres were coded accordingly as shown 
above. 
The synthesized CDHA powder and microsphere 
samples were characterized by X-ray powder 
diffraction (XRD) method (Shimadzu XDD1 X-Ray 
diffractometer, reflection mode, Japan) using CuK∝ 
radiation. The morphology of the CDHA granules 
and microspheres were observed under a scanning 
electron microscopy (JOEL JSM 5410 & JSM 5300, 
Japan). A few milligram of dried CDHA sample was 
deposited on a black adhesive tape, vacuum coated 
with gold film for 15 minutes and analyzed directly. 
The surface area of the microspheres was determined 
by the triple-point BET method (Sorptomatic 1990, 
USA) with nitrogen as the adsorbate gas and helium 
as an inert non-adsorbable carrier.
The effect of pH on the encapsulation of doxycyclin 
into CDHA microsphere was initially carried out in 
phosphate buffer saline (PBS) at room temperature 
to determine the suitable pH for loading of the 
maximum amount of the drug.  Buffers of varying pH 
were prepared and 10 mg of the drug was dissolved 
in the pH solutions. The CDHA microspheres were 
suspended in the above phosphate buffers for three 
hours. The microspheres were then separated and 
the concentration of the doxycyclin was measured 
using UV-Visible spectrophotometry (Varian Cary 5E 
UV-VIS-NIR Spectrophotometer, USA) with a 1-cm 
path length cuvette. Subsequently the loading was 
carried out at the optimal pH of the buffer. A typical 
UV visible spectrum of the doxycyclin hyclate has 
four characteristic peaks in the UV region as shown 
in Figure 1, and of the 4 peaks the very prominent 
peaks at 270 nm and 350 nm were monitored for 
the drug loading profile.
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Figure 1. Typical UV-visible spectrum of 
doxycycline.
To calculate the amount of drug loading, initially 
10 mg of CDHA microspheres were immersed in 
10 ml of PBS containing 10 mg of doxycyclin for 
24 hours. The microspheres were separated by 
centrifugation and dried at room temperature for 48 
hours. The amount of drug absorbed was calculated 
spectrometrically by finding the difference in 
doxycyclin concentration in the loading buffer, 
before, and after loading by using the equation:
Percentage drug loading = ((A-B)/A)*100 (1)
where A and B represent the initial and final drug 
concentrations of the buffer solution respectively 
and by varying the concentration of drug and the 
CDHA microspheres the maximum amount of 
loading of the drug was obtained.
The in vitro studies were carried out by soaking 
the drug loaded microspheres in sodium phosphate 
buffer solution as the medium for drug release at pH 
7.4 and 37oC. Triplicate samples of 10 mg of granules 
were suspended in 20 ml phosphate buffer in glass 
tubes. The tubes were placed in a bench top constant 
temperature water bath. At regular intervals of time, 
solutions were withdrawn and drug release profiles 
were obtained by the UV-visible spectrophotometry 
as mentioned above. The doxycyclin release from 
the specimen to the buffer was determined by 
measuring the absorbance values at the maximum 
observed at λ=270 nm.  The spectra were recordedfor 
every 30 minutes until there was no change in the 
subsequent values.
In vitro solubility studies of CDHA microspheres 
were carried out in phosphate buffer of pH 7.4 at 37oC. 
Dissolution experiments were performed by using 
0.1 g of the pure microspheres without drug loading 
in 50 ml of buffer of pH 7.4. Each tube containing 
buffer with the microspheres was maintained in a 
constant temperature water bath. The change in the 
pH of the buffer solution containing the microspheres 
was recorded at regular intervals of time during the 
dissolution experiments. All the experiments were 
performed in triplicate, by running three parallel 
independent measurements simultaneously. The 
weight loss was calculated by recording the initial 
and final weights of the microspheres. This weight 
loss indicates the percentage dissolution of the 
microspheres of various compositions.
Results and Discussion
The XRD pattern of the finally powdered oven dried 
CDHA samples are shown in Figure 2. The patterns 
essentially look similar to each other with major 
characteristic diffraction peaks corresponding to 
CDHA phase6. Although they have similar XRD 
pattern, the sample crystallinity as shown by the 
sharpness of the peak varies with the Ca/P ratio. The 
sample CD156 has the lowest crystallinity among 
the others.
Figure 2. XRD of CD164 (a), CD161 (b), and CD156 
(c) powder.
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The cell parameters of CDHA (Table 1) were 
calculated by least squares fit method and is found 
to decrease with increasing Ca/P ratio as expected 
for CDHAs.
Table 1. Unit cell parameters and surface area of 
CDHA samples.
CDHA 
sample(Ca/P)
Cell parameters (nm)
BET Area 
(m2/gm)
a = b c
1.56 0.943 0.688 38
1.61 0.943 0.686 72
1.64 0.941 0.686 54
Table 2. Surface area and drug release percentages 
of CDHA microspheres.
Gelatin 
concen-
tration
CDHA1.56MS CDHA1.61MS CDHA1.64MS
BET 
Area 
(m2/g)
% Drug 
release
BET Area 
(m2/g)
% Drug 
release
BET 
Area 
(m2/g)
% Drug release
4 28 39 40 53 19 24
6 35 48 75 80 25 29
8 31 46 53 65 22 26
2 Theta (deg.)
In
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n
s
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y
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A
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 U
n
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s
)
Figure 3. XRD of CD161 powder (a) 4CD161, (b) 
6CD161 (c) and 8CD161 (d) microspheres.
The specific surface area of the microspheres 
determined using BET isotherm is listed in Table 2. 
The surface area has been found to vary between 19 
to 75 m2 /g depending on the Ca/P ratio and gelatin 
concentration as similar to BCP microspheres8. The 
microspheres formed using 6% gelatin show larger 
surface area compared to other CDHA microspheres 
formed with different gelatin content. Similarly, the 
CDHA microspheres corresponding to Ca/P ratio 
of 1.61 have larger surface area than the CDHA 
microspheres with different Ca/P ratios. Hence, 
further characterization of CD161 microspheres has 
been carried out.
The typical XRD pattern of the CD161 
microspheres formed with various amounts of 
gelatin is shown in Figure 3. The patterns look similar 
to that of the starting CDHA powder as also shown 
in the same figure for comparison. This indicates the 
stability of the CDHA microspheres formed through 
heating at 650oC to remove the gelatin. The broad 
characteristic XRD peaks indicate the microcrys-
talline nature of the samples.
    
    
Figure 4.SEM micrographs of CD161 powder (a), 
4CD161MS (b), 6CD161MS (c) and 8CD161MS (d) 
microspheres.
The SEM micrograph of the powder and 
microspheres of CD161 is shown in Figure 4a-d. 
The morphology of the CD161 powder is spherulite 
and mostly agglomerated. There is a distinct 
difference in the morphology of the microparticles 
corresponding to a transition from irregular shape to 
spherical shape with smooth surfaces as a function 
of gelatin content.  Although, the 6CD161MS sample 
Victor and Sampath Kumar
102
indicates considerable agglomeration (Figure 4(b)), 
the microspheres are uniform and more spherical in 
contrast to other samples.    
The dissolution studies of the CDHA microspheres 
for all the Ca/P ratios prepared were carried out 
to determine the solubility of the resorbable 
bioceramics used. Both the pH variation of the 
buffer solution containing the microspheres and the 
weight of the microspheres were determined as a 
function of immersion time.
Figure5. pH variation of CDHA microspheres 
containing buffer as a function of time (a) and 
weight loss of the CD156, CD161 and CD164 
microspheres  (b).
The pH variation of the buffer solution 
containing the CDHA samples is shown in Figure 
5a. All the samples show drastic decrease of pH 
values initially followed by nearly a constant value 
depending on the Ca/P ratios. However the CD161 
and CD166 microspheres show an increase in pH 
after 50 hours. The overall trend in dissolution has 
been correlated with the nonstoichiometric behavior 
of CDHA ceramics based on a chemical model9. In 
this model, the initial stage of apatite dissolution 
consists of calcium detachment from the surface 
and subsequent detachment of phosphates from the 
surface10. Weight loss of the microspheres for all the 
three types of 6CDMS samples were observed during 
the dissolution studies (Figure 5b). The dissolution 
increases with a decrease in the Ca/P ratio as 
expected since more stable HA has a Ca/P ratio of 
1.66 while that of resorbable TCP is 1.5. Dissolution 
efficiency depends on the available surface area and 
the specific surface area of the 6CDMS microspheres 
varies from 25 to 75 m2/g. However, this parameter 
was found to be not related to Ca/P molar ratio and 
so the dissolution behavior.
The drug intake by the microspheres depends 
on the pH conditions of the buffer solution. The pH 
of 7 was found to have maximum loading of the 
drug and hence, selected for release study. The 
doxycycline seems to be stable at the various pHs 
studied. Higher amount of loading was shown by the 
CD161 microspheres.
The doxycycline release profiles of CD161 
microspheres are shown in Figure 6a. All the 
microspheres exhibits similar release profiles with 
a gra dual increase initially reaching a maximum 
value and then nearly a constant release profile. 
A maximum amount of about 80% drug release 
was observed for the 6CD161MS while 8CD161MS 
showed about 60% drug release. Both the 6CD161MS 
and 8CD161MS microspheres showed the maximum 
release at the ninth hour. As the 6CD161MS were 
relatively found to be uniformly spherical with a 
smoother surface, the observed release profile has 
been attributed to the surface bound drug8. It also 
has more surface area as indicated in Table 2. Hence, 
more amount of drug could have been absorbed 
on the 6CD161MS, which results in the maximum 
amount of drug release. The 4CD161MS were found 
to be larger which results in lesser amount of drug 
absorption and release at a shorter time interval. 
The results thus suggest optimum morphology, size, 
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and presence of micropores in 6CD161MS leading to 
the observed release profile.    
Figure 6. In vitro drug release profile of CD161 (a), 
CD156 (b), and CD164 (c) microspheres.
Figures 6b and 6c show the in vitro release profiles 
of CD156 and CD164 microspheres respectively. The 
profiles are similar to those obtained for the CD161 
microspheres. However, the maximum drug release 
is much lower (50% in CD156MS and 23% in CD164MS 
respectively) than that obtained for the CD161MS 
(80% in CD161MS). The above results correlated with 
the surface area measurements as indicated in Table 
2. The 6CD161MS has the highest surface area, which 
leads to more loading and ultimately better release 
characteristics. Compared to the other samples, the 
maximum amount of release (80% of drug) similar 
to a burst release of this sample may be due to the 
liberation of surface bound drug as indicated earlier. 
The open pore content in the microsphere is 
dependent on the gelatin concentration in starting 
CDHA/ gelatin mixture. Although the 8CD161MS 
microspheres were found to be porous, only 60% 
of the drug was released. This indicated that the 
size of the pores might be larger so as to not retain 
the doxycyclin drug. The 4CD161MS microspheres 
were found to be of larger size and without much 
pores and so these features result in lesser amount 
of drug absorption and release compared to other 
microspheres. The results thus suggest optimum 
morphology, size and presence of micropores in 
6CD161MS leading to the observed release profile. 
As the behavior of a particulate in the body depends 
on its morphology and porosity, the constant release 
of the drug thus can be controlled by appropriate 
selection of the microspheres by optimizing the 
Ca/P ratios to have the required features.
Conclusion
CDHA microspheres with optimum pore content 
and morphology were prepared. Doxycycline 
loading around physiological conditions leads to 
higher amount of loading. Maximum drug release 
was observed for the microspheres formed using 
6% gelatin. Release pattern strongly depends on 
the morphology of CDHA microspheres and an 
optimum release up to 80% has been recorded. The 
morphological features of the microsphere were 
found to correlate well with the in vitro doxycycline 
release and the surface area measurements 
(maximum in the case of 6 % gelatin).
Victor and Sampath Kumar
104
References
Di Silvio L, Bonfield W. 1999. Biodegradable 1. 
drug delivery system for the treatment of bone 
infection and repair. J Mater Sci: Mater Med 
10:653–8.
Mansho I, Wenyi Y, Takaaki A, Akira O, Naoki K. 2. 
1998. Synthesis of antibioticloaded interporous 
hydroxyapatite blocks by vacuum method and 
invitro release testing. Biomaterial 19:817-9. 
Alkhraisat MH, Rueda C, Cabrejos-Azama J, 3. 
Lucas-Aparicio J, Mariño FT,García-Denche 
JT, Jerez LB, Gbureck U, Cabarcos EL. 2010. 
Loading and release of doxycycline hyclate 
from strontium-substituted calciumphosphate 
cement. Acta Biomateralia 6:1522-8.
Thomazeau H, Langlais F. 1997. Antibiotic release 4. 
by tricalcium phosphate bone implantation, in 
vitro and in vivo pharmacokinetics of different 
galenic forms. Chirurgie 121:663-6.
Yamamura K, Iwata H, Yotsuyanagi T. 1992. 5. 
Synthesis of antibiotic-loaded hydroxyapatite 
beads and in vitro drug release testing. J Biomed 
Mater Res 26:1053-64.
Siddharthan A, Seshadri SK, SampathKumar 6. 
TS. 2004. Microwave accelerated synthesis of 
nanosized calcium deficient hydroxyapatite. J 
Mater Sci: Mater Med 15: 1279-84.
Bromberg LE, Debra KB, Phillip MF. 2001. No vel 7. 
periodontal drug delivery system fortreatment 
of periodontitis. Journal of Controlled Release 
71: 251–9.
Sunita PV, Sampath Kumar TS. 2008. BCP 8. 
ceramic microspheres as drug delivery carriers 
—synthesis, characterization and doxycycline 
release. J Mater Sci: Mater Med 19: 283-90.
Elena M, Alexandre MR, Nilce CCR, Gloria AS, 9. 
Josin CM, Gustavo TM. 2003. Dissolution of 
calcium-deficient hydroxyapatite synthesized at 
different conditions. Materials Characterization 
50:203-7.
Monteiro MM, Rocha NCC, Rossi AM, Soares 10. 
GA. 2003. Dissolution properties of calcium 
phosphate granules with different compositions 
in simulated bodyfluid. J Biomed Mater Res A 
65:299–305.
